These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17440052)

  • 21. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
    Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
    Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells.
    Krause G; Patz M; Isaeva P; Wigger M; Baki I; Vondey V; Kerwien S; Kuckertz M; Brinker R; Claasen J; Frenzel LP; Wendtner CM; Heider KH; Hallek M
    Leukemia; 2012 Mar; 26(3):546-9. PubMed ID: 21886169
    [No Abstract]   [Full Text] [Related]  

  • 23. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
    Weitzman J; Betancur M; Boissel L; Rabinowitz AP; Klein A; Klingemann H
    Leuk Lymphoma; 2009 Aug; 50(8):1361-8. PubMed ID: 19562616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tetraspanin CD37 protects against the development of B cell lymphoma.
    de Winde CM; Veenbergen S; Young KH; Xu-Monette ZY; Wang XX; Xia Y; Jabbar KJ; van den Brand M; van der Schaaf A; Elfrink S; van Houdt IS; Gijbels MJ; van de Loo FA; Bennink MB; Hebeda KM; Groenen PJ; van Krieken JH; Figdor CG; van Spriel AB
    J Clin Invest; 2016 Feb; 126(2):653-66. PubMed ID: 26784544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
    Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
    Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome
    Wurzer H; Filali L; Hoffmann C; Krecke M; Biolato AM; Mastio J; De Wilde S; François JH; Largeot A; Berchem G; Paggetti J; Moussay E; Thomas C
    Front Immunol; 2021; 12():619069. PubMed ID: 34108958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The lymphoid cell surface receptor NTB-A: a novel monoclonal antibody target for leukaemia and lymphoma therapeutics.
    Korver W; Singh S; Liu S; Zhao X; Yonkovich S; Sweeney A; Anton K; Lomas WE; Greenwood R; Smith A; Tran DH; Shinkawa P; Jimenez M; Yeung P; Aguilar G; Palencia S; Vatta P; Mueller M; Zhan X; Newton EM; Liu Y; Zhao J; Emtage P; Levy MD; Hsi ED; Funk WD; Abo A
    Br J Haematol; 2007 May; 137(4):307-18. PubMed ID: 17456053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
    Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
    Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CD37 antibodies for chronic lymphocytic leukemia.
    Robak T; Robak P
    Expert Opin Biol Ther; 2014 May; 14(5):651-61. PubMed ID: 24555705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.
    Leshchenko VV; Kuo PY; Shaknovich R; Yang DT; Gellen T; Petrich A; Yu Y; Remache Y; Weniger MA; Rafiq S; Suh KS; Goy A; Wilson W; Verma A; Braunschweig I; Muthusamy N; Kahl BS; Byrd JC; Wiestner A; Melnick A; Parekh S
    Blood; 2010 Aug; 116(7):1025-34. PubMed ID: 20427703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.
    Köksal H; Dillard P; Josefsson SE; Maggadottir SM; Pollmann S; Fåne A; Blaker YN; Beiske K; Huse K; Kolstad A; Holte H; Kvalheim G; Smeland EB; Myklebust JH; Inderberg EM; Wälchli S
    Blood Adv; 2019 Apr; 3(8):1230-1243. PubMed ID: 30979721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies.
    Qi J; Chen SS; Chiorazzi N; Rader C
    Methods; 2019 Feb; 154():70-76. PubMed ID: 30145356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxicity of the CD37 antibody BI 836826 against chronic lymphocytic leukaemia cells in combination with chemotherapeutic agents or PI3K inhibitors.
    Krause G; Baki I; Kerwien S; Knödgen E; Neumann L; Göckeritz E; Landwehr T; Heider KH; Hallek M
    Br J Haematol; 2016 Jun; 173(5):791-4. PubMed ID: 26271483
    [No Abstract]   [Full Text] [Related]  

  • 35. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.
    Wild J; Schmiedel BJ; Maurer A; Raab S; Prokop L; Stevanović S; Dörfel D; Schneider P; Salih HR
    Leukemia; 2015 Aug; 29(8):1676-83. PubMed ID: 25710310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
    Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
    J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
    Ward E; Mittereder N; Kuta E; Sims GP; Bowen MA; Dall'Acqua W; Tedder T; Kiener P; Coyle AJ; Wu H; Jallal B; Herbst R
    Br J Haematol; 2011 Nov; 155(4):426-37. PubMed ID: 21902688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tetraspanin CD37 Regulates β2 Integrin-Mediated Adhesion and Migration in Neutrophils.
    Wee JL; Schulze KE; Jones EL; Yeung L; Cheng Q; Pereira CF; Costin A; Ramm G; van Spriel AB; Hickey MJ; Wright MD
    J Immunol; 2015 Dec; 195(12):5770-9. PubMed ID: 26566675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate
    Maaland AF; Heyerdahl H; O'Shea A; Eiriksdottir B; Pascal V; Andersen JT; Kolstad A; Dahle J
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2311-2321. PubMed ID: 31309259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The tetraspanin CD37 orchestrates the α(4)β(1) integrin-Akt signaling axis and supports long-lived plasma cell survival.
    van Spriel AB; de Keijzer S; van der Schaaf A; Gartlan KH; Sofi M; Light A; Linssen PC; Boezeman JB; Zuidscherwoude M; Reinieren-Beeren I; Cambi A; Mackay F; Tarlinton DM; Figdor CG; Wright MD
    Sci Signal; 2012 Nov; 5(250):ra82. PubMed ID: 23150881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.